KevinMBiglanMDMPH

Neurology • Rochester, NY

Movement Disorder

Professor, Neurology, Center for Human Experimental Therapeutics, University of Rochester School of Medicine & Dentistry

Join to view full profile

Dr. Biglan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Biglan's full profile

Already have an account?

Office
919 Westfall Rd
Bldg C, Suite 215
Rochester, NY 14618
Phone+1 585-341-7500

Fax+1 585-341-7510

Education & Training

University of RochesterFellowship, Neuromuscular Medicine (Neurology), 2000 - 2003
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Neurology, 1997 - 2000
Main Line Health System/Lankenau Medical CenterInternship, Internal Medicine, 1996 - 1997
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1996

Certifications & Licensure

NY State Medical License 2000 - 2025
MD State Medical License 2003 - 2006
PA State Medical License 1997 - 2002
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

A Pilot, Randomized Controlled Trial of Group Visits for Persons With Parkinson's Disease Start of enrollment: 2007 Sep 01
Completed
Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population Start of enrollment: 2008 Apr 01
Completed
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Start of enrollment: 2009 Sep 01
Terminated
Phase 3
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) Start of enrollment: 2010 Feb 01
Completed
Phase 2
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Recruiting
Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes Start of enrollment: 2014 Mar 01
Completed
Not Applicable
Remote Access to Care, Everywhere, for Parkinson Disease Start of enrollment: 2014 Mar 01
Completed
Not Applicable
Efficacy of Isradipine in Early Parkinson Disease Start of enrollment: 2014 Nov 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia.
Chakib Battioui, Albert Man, Melissa Pugh, Jian Wang, Xiangnan Dang
Digital Biomarkers. 2023-06-21
22 citations
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.
Kevin Biglan, Leanne Munsie, Kjell A. Svensson, Paul A. Ardayfio, Melissa Pugh
Movement Disorders. 2021-12-02
4 citations
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson ...
Darren Wilbraham, Kevin Biglan, Kjell A. Svensson, Max Tsai, Melissa Pugh
Clinical Pharmacology in Drug Development. 2021-10-19

Press Mentions

Where Teleneurology Is Expanding, and Who Is Paying for ItDecember 8th, 2016
AMC Health and University of Rochester Medical Center Deploy Virtual Video Visits for Phase III Clinical Trial in Parkinson’s Disease: REACT-PD StudyJune 22nd, 2016
Medical School Launches Parkinson’s Telemedicine SolutionMay 10th, 2016

Professional Memberships

International Parkinson and Movement Disorder Society - MDS
Member